Pharmacovigilance Outsourcing Market Outlook 2026-2030: Investment Trends, Strategic Profiles and Revenue Share Outlook
Dublin, Sept. 15, 2026 (GLOBE NEWSWIRE) -- "Pharmacovigilance Outsourcing Market Report 2026" has been added to ResearchAndMarkets.com's offering.
Pharmacovigilance Outsourcing Market to Reach $16.09 Billion by 2030 as Clinical Trials and Safety Reporting Requirements Expand
The global pharmacovigilance outsourcing market is experiencing rapid growth as pharmaceutical and biotechnology companies strengthen drug safety monitoring, address increasingly complex regulatory requirements, and improve operational efficiency. The market is projected to grow from $7.24 billion in 2025 to $8.51 billion in 2026, representing a compound annual growth rate (CAGR) of 17.6%.
Historical market expansion has been supported by the rising number of new drug approvals, greater awareness of pharmacovigilance requirements among pharmaceutical companies, limited in-house pharmacovigilance expertise, heightened regulatory scrutiny, and the globalization of clinical research. As drug development programs become more international and safety reporting obligations increase, organizations are turning to specialized outsourcing providers for scalable expertise, technology, and compliance support.
The pharmacovigilance outsourcing market is forecast to reach $16.09 billion by 2030, expanding at a CAGR of 17.2%. Growth during the forecast period is expected to be driven by the integration of artificial intelligence and advanced data analytics into pharmacovigilance processes, increased engagement with contract research organizations and business process outsourcing providers, adoption of cloud-based safety platforms, broader global reporting requirements, and continued investment in IT infrastructure.
Key pharmacovigilance outsourcing market trends include the automation of adverse drug reaction capture and case processing, expansion of knowledge management and data integration solutions, and a stronger focus on risk management, quality assurance, and audit readiness. Pharmaceutical companies are also expected to increase their use of outsourced services to manage growing case volumes, maintain reporting accuracy, and meet evolving regulatory standards across multiple jurisdictions.
The increasing number of clinical trials is a significant factor supporting market growth. This expansion is being fueled by rising chronic disease prevalence, greater emphasis on precision medicine, supportive regulatory frameworks, and the continued globalization of research activity. Outsourced pharmacovigilance services enable trial sponsors to strengthen safety monitoring, access specialized resources, maintain regulatory compliance, and improve the efficiency of adverse event processing and reporting.
According to the Association of the British Pharmaceutical Industry, the number of industry-sponsored clinical trials initiated in the UK increased from 411 in 2022 to 426 in 2023. The increase highlights the growing need for reliable safety surveillance and regulatory reporting throughout the clinical development lifecycle. As research pipelines expand, demand for pharmacovigilance outsourcing services is expected to rise accordingly.
Technology innovation is also reshaping the competitive landscape. Providers are developing cloud-based data platforms that integrate multiple safety information sources, streamline case processing, and improve the coding, classification, and reporting of adverse events. These systems support scalable, compliant, and auditable pharmacovigilance operations while enabling long-term post-authorization safety studies across diverse therapeutic areas.
In December 2023, Thermo Fisher Scientific introduced CorEvidence to enhance clinical research registries and safety data management. The solution supports pharmacovigilance case processing by integrating data sources and improving adverse event workflows. Its capabilities are designed to strengthen compliant safety management and support post-authorization research through CorEvitas clinical research registries.
Investment and acquisition activity is further contributing to the development of the pharmacovigilance outsourcing industry. In November 2023, Permira Advisers LLP acquired Ergomed PLC for $904 million. The transaction is intended to support Ergomed's next phase of growth by using Permira's financial resources, industry expertise, and global network to expand the company's commercial, technological, and geographic presence. It may also facilitate strategic acquisitions across the contract research organization and pharmacovigilance sectors.
North America was the largest region in the pharmacovigilance outsourcing market in 2025, while Asia-Pacific is expected to be the fastest-growing region during the forecast period. The market covers Asia-Pacific, Southeast Asia, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. Countries included in the analysis are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, the UK, the USA, Canada, Italy, and Spain.
Markets Covered:
1) By Type: Adverse Drug Reaction Capture (ADR); Case Processing; Reporting And Submission; Report Publishing; Quality Check; Risk Management; Knowledge Management; Enabling Architecture
2) By Service Provider: Contract Research Organization; Business Processing Outsourcing
3) By End User: Pharmaceutical Industry; Research Organization; Other End Users
Subsegments:
1) By Adverse Drug Reaction Capture (ADR): Automated ADR Reporting Tools; Manual ADR Reporting Solutions; ADR Data Mining Software
2) By Case Processing: Case Intake and Triage Services; Medical Review and Evaluation Services; Data Entry and Management Services
3) By Reporting And Submission: Regulatory Reporting Services; Submission to Health Authorities; Compliance Tracking Services
4) By Report Publishing: Clinical Study Report Publishing; Safety Update Report Publishing; Final Study Report Publishing
5) By Quality Check: Quality Assurance Services; Audit and Inspection Services; Compliance Monitoring Services
6) By Risk Management: Risk Assessment Services; Risk Minimization Strategies; Benefit-Risk Evaluation Services
7) By Knowledge Management: Data Management Solutions; Pharmacovigilance Database Management; Knowledge Sharing Platforms
8) By Enabling Architecture: IT Infrastructure Solutions; Data Integration Services; Technology Platform Support
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Key Attributes:
Companies Featured
The companies featured in this Pharmacovigilance Outsourcing market report include:
For more information about this report visit https://www.researchandmarkets.com/r/4el93o
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.